G. Walmsley Graham - 03 Jun 2025 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role: Director
Signature: /s/ Jonathan Young, Attorney-in-Fact
Issuer symbol: AKRO
Transactions as of: 03 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 05 Jun 2025, 16:05:18 UTC
Previous filing: 27 Mar 2025
Next filing: 13 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Graham G. Walmsley	Director	C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO	/s/ Jonathan Young, Attorney-in-Fact	05 Jun 2025	0001777517

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKRO	Common Stock	Award	$0	+9,398	+433%	$0.000000	11,566	03 Jun 2025	Direct	F1
holding	AKRO	Common Stock						1,200,000	03 Jun 2025	See Footnote	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs shall vest in full on the earlier of (i) June 3, 2026, and (ii) the next annual meeting of the Company's stockholders, subject to the director's continued service on the Board.
F2	The shares are held by Logos Global Master Fund LP ("Logos Master Fund") and Logos Opportunities Fund IV LP ("LOF IV"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. Logos Opportunities IV GP LLC ("GP IV") is the general partner of LOF IV and the Reporting Person is a managing member of GP IV. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Content

These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs shall vest in full on the earlier of (i) June 3, 2026, and (ii) the next annual meeting of the Company's stockholders, subject to the director's continued service on the Board.

The shares are held by Logos Global Master Fund LP ("Logos Master Fund") and Logos Opportunities Fund IV LP ("LOF IV"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. Logos Opportunities IV GP LLC ("GP IV") is the general partner of LOF IV and the Reporting Person is a managing member of GP IV. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.